[{"orgOrder":0,"company":"Bayside Health","sponsor":"Merck & Co | Austin Hospital, Melbourne Australia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Oncology","graph2":"Phase III","graph3":"Bayside Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayside Health \/ Merck & Co | Austin Hospital, Melbourne Australia","highestDevelopmentStatusID":"10","companyTruncated":"Bayside Health \/ Merck & Co | Austin Hospital, Melbourne Australia"}]

Find Clinical Drug Pipeline Developments & Deals for Elbasvir

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Bayside Health

                          Country arrow
                          FNCE
                          Not Confirmed

                          Bayside Health

                          Country arrow
                          FNCE
                          Not Confirmed

                          Details : Elbasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Hepatocellular.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 14, 2020

                          Lead Product(s) : Elbasvir

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Merck & Co | Austin Hospital, Melbourne Australia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank